DIAMANTE - Diseases Infectious Analysis Microflora Antibiotic Effect
- Registration Number
- NCT00424905
- Lead Sponsor
- Sanofi
- Brief Summary
To assess the effects of Bacillus clausii (Enterogermina®) on fecal microbial flora (using Polymerase Chain Reaction - Denaturing Gradient Gel Electrophoresis - PCR-DGGE - Method) in antibiotic-treated children with complicated acute otitis media or beta-hemolytic streptococcal pharyngo-tonsillitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Subjects with persistency of symptoms and requiring antibiotics for bacterial upper respiratory tract infections, i.e. complicated acute otitis media (diagnosed by otoscopic examination) or beta-haemolytic streptococcal pharyngo-tonsillitis (diagnosed by pharyngeal swab and rapid antigen detection test or positive culture);
- Outpatients or patients attending an emergency room for both diagnoses, and inpatients in case of complicated acute otitis media;
- Written informed consent from both parents.
Exclusion Criteria
- History of clinically significant chronic diseases, or chronic diseases necessitating the use of continuous drug therapies, or of any disease that may interfere with the successful completion or the objectives of the trial;
- Clinical evidence of relevant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological or of any disease that may interfere with the successful completion or the objectives of the trial;
- Use of antibiotics, prebiotics or probiotics (medications or dietetic supplements) in the last 2 weeks prior to study entry;
- Hypersensitivity to the investigational product;
- Subjects enrolled in another trial in the previous three months.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Bacillus clausii Enterogermina® vials containing 2×109 spores of polyantibiotic resistant Bacillus clausii (test drug)
- Primary Outcome Measures
Name Time Method Changes of microbial composition of fecal bacterial flora by PCR-DGGE analysis. between samples obtained at baseline and follow-up
- Secondary Outcome Measures
Name Time Method Changes from baseline of body weight During the total study period Assessment of abdominal symptoms Daily Presence of Bacillus clausii spores in feces after heat shock treatment on selective medium. Number and rate of patients with GI symptoms and time to first development of symptoms. recorded in a daily diary card for the total study period
Trial Locations
- Locations (1)
Sanofi-Aventis
🇮🇹Milan, Italy